A model of mild hypoglycemia

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Current Medical Research and Opinion

• Publication date

  2015-03-17

• Fields of study

  Medicine, Mathematics

• Identifiers
  DOI 10.1185/03007995.2015.1020363PMID 25690489
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States

  2015cited by this paper
• Diabetes duration and the efficacy and safety of insulin glargine versus comparator treatment in patients with type 2 diabetes mellitus.

  2014influential reference
• Optimal therapy of type 2 diabetes: a controversial challenge

  2014cited by this paper
• Composite efficacy parameters and predictors of hypoglycaemia in basal‐plus insulin therapy—a combined analysis of 713 type 2 diabetic patients

  2014cited by this paper
• Rates and risk of hospitalisation among patients with type 2 diabetes: retrospective cohort study using the UK General Practice Research Database linked to English Hospital Episode Statistics

  2013cited by this paper
• Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus

  2013influential reference
• Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society

  2013cited by this paper
• Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.

  2013cited by this paper
• Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses

  2012cited by this paper
• Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta‐analysis

  2012cited by this paper
• Incidence and predictors of hypoglycaemia in type 2 diabetes – an analysis of the prospective DiaRegis registry

  2012cited by this paper
• Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

  2012cited by this paper
• Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes - A Systematic Review of the Evidence

  2012cited by this paper
• Predictors of Emergency Department and Outpatient Visits for Hypoglycemia in Type 2 Diabetes: An Analysis of a Large US Administrative Claims Database

  2012cited by this paper
• Incidence and Cost of Hypoglycemia Among Patients with Type 2 Diabetes in the United States: Analysis of a Health Insurance Database

  2011cited by this paper
• Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study

  2011cited by this paper
• Describing hypoglycemic events using extensions of the Cox model

  2011cited by this paper
• Standards of Medical Care in Diabetes—2011

  2011cited by this paper
• The impact of non-severe hypoglycemic events on work productivity and diabetes management.

  2011cited by this paper
• An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia

  2011influential reference
• Evidence Linking Hypoglycemic Events to an Increased Risk of Acute Cardiovascular Events in Patients With Type 2 Diabetes

  2011cited by this paper
• Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health‐related quality of life. A prospective cohort study in primary care

  2011cited by this paper
• Severe hypoglycemia and risks of vascular events and death.

  2010cited by this paper
• Hypoglycemia, Diabetes, and Cardiovascular Events

  2010cited by this paper
• Risk factors for symptomatic hypoglycaemia in people with type 2 diabetes mellitus initiated on insulin therapy: evidence from the CREDIT study

  2010cited by this paper
• The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study

  2010cited by this paper
• The global burden of diabetes and its complications: an emerging pandemic

  2010cited by this paper
• Glucose control and vascular complications in veterans with type 2 diabetes.

  2009cited by this paper
• Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine*

  2009cited by this paper
• Frequency of hypoglycemia and its significance in chronic kidney disease.

  2009cited by this paper
• Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT

  2009cited by this paper
• Hypoglycaemia with Oral Antidiabetic Drugs

  2009cited by this paper
• Dipeptidyl Peptidase-IV Inhibitors: Pharmacological Profile and Clinical Use

  2008cited by this paper
• Hypoglycemia: still the limiting factor in the glycemic management of diabetes.

  2008cited by this paper
• Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia

  2008cited by this paper
• Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.

  2007cited by this paper
• Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration

  2007cited by this paper
• A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events

  2007cited by this paper
• Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.

  2007cited by this paper
• Standards of medical care in diabetes.

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

  2006cited by this paper
• Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.

  2006cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Frequency and predictors of hypoglycaemia in Type 1 and insulin‐treated Type 2 diabetes: a population‐based study

  2005cited by this paper
• Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus.

  2004cited by this paper
• Hypoglycemia as a barrier to glycemic control.

  2004cited by this paper
• GUIDE study: double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patients

  2004cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004cited by this paper
• Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients

  2003cited by this paper
• Validation of the archimedes diabetes model.

  2003cited by this paper
• Hypoglycemia in diabetes.

  2003cited by this paper
• Hypoglycemia in patients with type 2 diabetes mellitus.

  2001cited by this paper
• Symptoms of hypoglycemia, thresholds for their occurrence, and hypoglycemia unawareness.

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas.

  1997cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper

• Data-based modeling for hypoglycemia prediction: Importance, trends, and implications for clinical practice

  2023cites this paper
• Is hypoglycemia expensive in China?

  2021cites this paper
• [Cost-utility study of the combination of metformin with the different glucose-lowering medication classes in adults 80 aged and older].

  2020cites this paper
• The Burden of Hypoglycemia in Patients With Insulin-Treated Diabetes Mellitus in China: Analysis of Electronic Medical Records From 4 Tertiary Hospitals.

  2020cites this paper
• Hypoglycemia

  2020cites this paper
• Hypoglycemia

  2019cites this paper
• Association between mild and severe hypoglycemia in people with type 2 diabetes initiating insulin.

  2017cites this paper
• The Cost of Hypoglycemia

  2017cites this paper
• Incidence and cost of hypoglycemic events requiring medical assistance in a hospital setting in Denmark.

  2016cites this paper
• Costs associated with emergency care and hospitalization for severe hypoglycemia.

  2016cites this paper
• Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada

  2016influential citation